Prostate Cancer

The improved survival was observed in patients treated at high-volume radiation centers with external-beam radiation therapy plus androgen-deprivation therapy.

MRI-guided focused ultrasound ablation was highly effective with minimal side effects.

In a phase 3 trial, biochemical failure-free survival and disease-free survival were improved with prophylactic whole-pelvic radiotherapy versus prostate-only radiotherapy.

Abiraterone acetate, enzalutamide, and apalutamide are highlighted among the standards of care for initial treatment.

"Here we show that there are clear benefits in delaying radiographic progression or death, [PSA] progression, and other outcomes in the largest groups of men with metastatic hormone-sensitive prostate cancer and lymph node and bone metastases,” says Andrew Armstrong, MD.

The risks of erectile dysfunction or rectourethral fistula post-cryosurgery were also not increased by prior surgical interventional therapy for benign prostatic hyperplasia.

Stereotactic body radiotherapy produced similar efficacy without added toxicity compared with standard radiation in men with advanced prostate cancer.

The PD-L1 inhibitor was approved based on data from the phase 3 JAVELIN Bladder 100 study.

The GnRH receptor antagonist was approved by the FDA in December 2020 for the treatment of patients with advanced prostate cancer.

The boost improved biochemical disease-free survival without negatively affecting safety and quality of life.

The trend in prostate cancer aligns with an overall decline in cancer-related suicide across all tumor types.

The study contradicts the findings from an Italian study published in 2020.

Higher medical mistrust and concerns about masculinity likely contribute to the increased decision regret.

The integrated radiomic-clinicopathologic nomogram (RadClip) was a better prognosticator of biochemical recurrence-free survival and adverse pathology than other standard tools.

Health literacy was associated with a reduced likelihood that a patients' screening decision would be affected by the screening-promoting effects of shared decision making.

Among patients with 6 years’ follow-up, no differences were observed between ultra-hypofractionation and conventional fractionation in the rates of clinically relevant deterioration in overall urinary bother, overall bowel bother, overall sexual bother, or global health/QoL.

The investigators drew specific attention to the impact of their findings on prostate ablation therapy.

In the ARAMIS trial, darolutamide reduced the risk of death by 31% compared with placebo in men with nonmetastatic castration-resistant prostate cancer.

The technique fails to demonstrate benefits for prostate cancer recurrence and metastases.

The researchers also found evidence supporting the role of germline variation in healthcare disparities related to prostate cancer.

“Instead of just offering a select-few treatment options, ideally you would like to be able to offer patients a whole menu of treatments and have an educated conversation regarding the risks and benefits for each of these treatment options," says Rian Dickstein, MD.

The FDA approved relugolix in December 2020 for the treatment of patients with advanced prostate cancer.

The research involved examining circulating markers of inflammation in patients with prostate cancer receiving androgen-deprivation therapy.